Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $35.35M (cash outflow) fell 26.8% year over year, ahead of the -44.6% change in trailing-twelve-month net income. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$131.3M (-4.2%) for the fiscal year ending Dec 2026, a step up from the -17.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.35M+0.4% QoQ
- Last fiscal yearDec 2025
- -$137.06M-17.4% YoY
- LTMMar 2026
- -$124.13M-44.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -26.8% | +28.1% | +54.9 pp |
| 1 year | -17.4% | -4.2% | +13.2 pp |
| 3-year CAGR | -16.7% | -7.2% | +9.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (137.06M) USD
- Year-over-year change
- +17.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (137.06M) | +17.4% |
| FY2024 | 2024-12-31 | (165.87M) | +43.2% |
| FY2023 | 2023-12-31 | (292.19M) | -23.2% |
| FY2022 | 2022-12-31 | (237.11M) | -42.8% |
| FY2021 | 2021-12-31 | (166.09M) | — |
Net Income vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's LTM Mar 2026 net income of $124.13M is the 2nd largest of the 11 companies compared; the peer median is $60.12M.
- Its year-over-year change of -44.6% is the 9th highest of 11, against a peer median of -30.5%.
- Over three fiscal years its annual growth of -16.7% compares with a peer median of -10.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $124.13M | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $88.87M | -31.7% | -6.3% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M | +21.4% | +12.6% | — |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $49.87M | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | $47.38M | -39.3% | -31.6% | — | |
| LTM Mar 2026 | $43.6M | +98.3% | -25.7% | 96.7% | |
| LTM Mar 2026 | $34.98M | +67.3% | +52.9% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M | -67.7% | -30.2% | 288.3% |
| Peer median (excluding ZNTL) | $60.12M | -30.5% | -10.4% | 154.2% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (166.09M) | (237.11M) | (292.19M) | (165.87M) | (137.06M) |
| Depreciation & Amortization | 544K | 1.43M | 1.39M | 1.29M | 739K |
| Deferred Income Tax | (2.51M) | (769K) | (853K) | 0 | 0 |
| Stock-Based Compensation | 35.74M | 46.84M | 54.82M | 67.27M | 20.72M |
| Change in Working Capital | 16.61M | 13.25M | 5.86M | (16.54M) | (9.12M) |
| Accounts Receivables | 413K | 0 | 0 | (5M) | 5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13.96M | 15.53M | 10.92M | (18.02M) | (17.32M) |
| Other Working Capital | 2.23M | (2.28M) | (5.06M) | 6.48M | 3.19M |
| Other Non-Cash Items | (38.38M) | 12.61M | 23.15M | (57.01M) | (526K) |
| Operating Cash Flow | (154.09M) | (163.75M) | (207.82M) | (170.86M) | (125.25M) |
| Capital Expenditures | (6.11M) | (2.55M) | (583K) | (221K) | 0 |
| Acquisitions (Net) | (14.32M) | 111.63K | 0 | 65K | 0 |
| Purchases of Investments | (363.51M) | (533.16M) | (549.18M) | (127.96M) | (139.49M) |
| Sales of Investments | 365.82M | 421.53M | 505.31M | 304.68M | 270.41M |
| Other Investing Activities | 0 | (111.63K) | 0 | 0 | 698K |
| Investing Cash Flow | (18.12M) | (114.18M) | (44.46M) | 176.56M | 131.62M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 179.67M | 261.04M | 237.3M | 349K | (4.28M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.15M) | 0 | 0 | (241K) | 0 |
| Financing Cash Flow | 178.52M | 261.04M | 237.3M | 108K | (4.28M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 6.31M | (16.89M) | (14.98M) | 5.81M | 2.09M |
| Free Cash Flow | (160.2M) | (166.3M) | (208.41M) | (171.08M) | (125.25M) |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.